CNTA
Centessa Pharmaceuticals plc
NASDAQ · Healthcare · Biotechnology · GB
$40.50
+0.00%Price chart
May 28Jun 2Jun 5Jun 10Jun 15Jun 18Jun 24Jun 29
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−23.0x
Market Cap
$6.27B
MomentumView details →
1D Return
+0.00%
YTD Return
+61.94%
RSI (14)
78.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−23.0x
Market Cap
$6.27B
RSI (14)
78.2
MomentumView details →
1D Return
+0.00%
YTD Return
+61.94%
SummaryUpdated Mar 1, 2026
Centessa Pharmaceuticals plc (NASDAQ:CNTA) is a clinical-stage biopharmaceutical company founded in 2020 and based in Altrincham, United Kingdom. The company went public in May 2021 through an initial public offering. Centessa operates as a pharmaceutical development company focused on discovering, developing, and delivering medicines across multiple therapeutic areas including rare diseases, oncology, and autoimmune conditions. The company maintains a diverse pipeline of drug candidates ranging from early-stage discovery through late-stage clinical trials.
Similar companies
Latest newsMore news →
Nexera Pharma announced it will receive a milestone payment of $8.6 million from Centessa Pharmaceuticals, a subsidiary of Eli Lilly, due to progress in late-stage development of an OX2R agonist.2d agoEli Lilly acquired Centessa Pharmaceuticals for $7.8 billion.59d agoEli Lilly completed its acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders.72d ago